Diet and drug therapy for lipoprotein (a)

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalCurrent Opinion in Lipidology
Volume6
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Diet Therapy
Drug therapy
Lipoprotein(a)
Nutrition
Drug Therapy
Niacin
Lipoproteins
Atherosclerosis
Estrogens
Cardiovascular Diseases
Plasmas

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Diet and drug therapy for lipoprotein (a). / Berglund, Lars.

In: Current Opinion in Lipidology, Vol. 6, No. 1, 1995, p. 48-56.

Research output: Contribution to journalArticle

@article{625e40f775e94d2a98b1820e92e8d144,
title = "Diet and drug therapy for lipoprotein (a)",
abstract = "Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).",
author = "Lars Berglund",
year = "1995",
doi = "10.1097/00041433-199502000-00011",
language = "English (US)",
volume = "6",
pages = "48--56",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Diet and drug therapy for lipoprotein (a)

AU - Berglund, Lars

PY - 1995

Y1 - 1995

N2 - Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).

AB - Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).

UR - http://www.scopus.com/inward/record.url?scp=0028942016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028942016&partnerID=8YFLogxK

U2 - 10.1097/00041433-199502000-00011

DO - 10.1097/00041433-199502000-00011

M3 - Article

C2 - 7735716

AN - SCOPUS:0028942016

VL - 6

SP - 48

EP - 56

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 1

ER -